Back to results
US 11,692,036 B2Granted
Anti-CTLA4 antibodies and methods of making and using the same
AssigneeAdagene Inc.
InventorsPeter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
Life of this patent
Estimating the term…
Abstract
Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
Claims28
An anti-CTLA4 antibody, wherein the antibody comprises:
- a) an HVR-H1 comprising the amino acid sequence YSITSGYYWAWI (SEQ ID NO:
- 19), an HVR-H2 comprising the amino acid sequence VSSISGSGSTTYYADSVKGRF (SEQ ID NO:
- 31), an HVR-H3 comprising the amino acid sequence ARDGFGYFDY (SEQ ID NO:
- 41), an HVR-L1 comprising the amino acid sequence SASSSVSYVY (SEQ ID NO:
- 54), an HVR-L2 comprising the amino acid sequence DASSLESGV (SEQ ID NO:
- 67), and an HVR-L3 comprising the amino acid sequence YCVQGLQTPWT (SEQ ID NO:
- 71);
- b) an HVR-H1 comprising the amino acid sequence YSISSGYHWSWI (SEQ ID NO:
- 23), an HVR-H2 comprising the amino acid sequence LARIDWDDDKYYSTSLKSRL (SEQ ID NO:
- 35), an HVR-H3 comprising the amino acid sequence ARSYVYFDY (SEQ ID NO:
- 45), an HVR-L1 comprising the amino acid sequence RASQSVRGRFLA (SEQ ID NO:
- 58), an HVR-L2 comprising the amino acid sequence DASNRATGI (SEQ ID NO:
- 66), and an HVR-L3 comprising the amino acid sequence YCQQSSSWPPT (SEQ ID NO:
- 75);
- c) an HVR-H1 comprising the amino acid sequence FTFSGYAIHWV (SEQ ID NO:
- 26), an HVR-H2 comprising the amino acid sequence IGIISPSGGGTKYAQKFQGRV (SEQ ID NO:
- 37), an HVR-H3 comprising the amino acid sequence ARHPFAY (SEQ ID NO:
- 48), an HVR-L1 comprising the amino acid sequence RASQSVDFYGISFLD (SEQ ID NO:
- 61), an HVR-L2 comprising the amino acid sequence DASNRATGI (SEQ ID NO:
- 66), and an HVR-L3 comprising the amino acid sequence YCQQYVSSPPEYT (SEQ ID NO:
- 78);
- d) an HVR-H1 comprising the amino acid sequence YTFSGYAIHWV (SEQ ID NO:
- 28), an HVR-H2 comprising the amino acid sequence IGIISPSGGGTKYAQKFQGRV (SEQ ID NO:
- 37), an HVR-H3 comprising the amino acid sequence ARLYDVAY (SEQ ID NO:
- 50), an HVR-L1 comprising the amino acid sequence RASQSVDFHGKSFLH (SEQ ID NO:
- 63), an HVR-L2 comprising the amino acid sequence DASSLESGV (SEQ ID NO:
- 67), and an HVR-L3 comprising the amino acid sequence of YCEQSLEVPFT (SEQ ID NO:
- 80);
- or
- e) an HVR-H1 comprising the amino acid sequence FTFSDYAIHWV (SEQ ID NO:
- 18), an HVR-H2 comprising the amino acid sequence IGIISPSGGSTKYAQKFQGRV (SEQ ID NO:
- 38), an HVR-H3 comprising the amino acid sequence ARLGYGYFDV (SEQ ID NO:
- 51), an HVR-L1 comprising the amino acid sequence RASQSVDFYGISFLH (SEQ ID NO:
- 64), an HVR-L2 comprising the amino acid sequence DASSLESGV (SEQ ID NO:
- 67), and an HVR-L3 comprising the amino acid sequence YCVQALQLPLT (SEQ ID NO:
- 81).
33 more elements
A polynucleotide comprising a sequence selected from the group consisting of SEQ ID NOS:
- 108-133.
Dependencies are inferred from the claim text.